CBU
CPRX

CIBC Bancorp USA’s Catalyst Pharmaceutical CPRX Stock Holding History

CIBC Bancorp USA’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$246K Buy
+9,943
New +$237K ﹤0.01% 1506
2025
Q3 		$243K Buy
+12,341
New +$254K ﹤0.01% 1180

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

CIBC Bancorp USA's CPRX Position: Q1 2026 in Review

CIBC Bancorp USA opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 9,943 shares worth $246K. The stake represents ﹤0.01% of the portfolio and ranks #1506 among its holdings. This is a return to the name: CIBC Bancorp USA previously reported a position in CPRX as recently as Q3 2025.

CIBC Bancorp USA first reported a position in CPRX in Q3 2025 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • CIBC Bancorp USA held 9,943 shares of Catalyst Pharmaceutical worth $246K as of Q1 2026.
  • Catalyst Pharmaceutical was a new CIBC Bancorp USA position in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q1 2026, its #1506 holding.
  • CIBC Bancorp USA first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 2 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on CIBC Bancorp USA's 13F filing for Q1 2026, filed 12 May 2026.